Scientific publication with Newspaper speed
HIGH IMPACT, OUTSTANDING EDITORIAL BOARD, OVERNIGHT PUBLICATION, OPEN ACCESS in PUBMED, PROMOTION, HIGH VISIBILITY
Oncotarget publishes high-impact research papers of general interest and outstanding significance and novelty in all areas of biology and medicine: in translational, basic and clinical research including but not limited to cancer research, oncogenes, oncoproteins and tumor suppressors, signaling pathways as potential targets for therapeutic intervention, shared targets in different diseases (cancer, benign tumors, atherosclerosis, eukaryotic infections, metabolic syndrome and other age-related diseases), chemotherapy and new therapeutic strategies. In 2010-2011, Oncotarget also publishes regular research papers.
To ensure the highest impact on the field, we now publish Priority articles and reviews over-(two)-night in PubMed.
If your research paper was mistakenly rejected by other leading journals, you may read it in PubMed in two nights after submission to Oncotarget (see our unique 2 night policy). Complemented by commentaries indexed in PubMed, your paper will have an immediate impact.
Oncotarget now publishes up-to-date Reviews, Perspectives, Research Summaries (including lifelong), Concepts, Commentaries, Research Feedback, Insights, Opinion pieces and focused review series. Accepted papers will appear in PubMed in two nights, making such articles timely - ensuring their maximal impact.
|06/28/2012||Launched in May 2010, Oncotarget has received IF2011: 4.784. In comparison...|
|01/18/2012||A digital archive of papers published in Oncotarget is now available though the U.S. National Library of Medicine's PubMed Central (PMC) database.|
|12/21/2010||Oncotarget has been accepted for indexing at PubMed/Medline. All papers have appeared on PubMed/Medline.|
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Impact Journals LLC 2008